DR. GEORGE SCHEELE

 CURRICULUM VITAE

 INVENTIONS

 PATENTS

 COMPANY FOUNDER

 PH Pharmaceuticals Inc.
 Viral Shield
  Pharmaceuticals Inc.
 NovaLife Inc.
 La Jolla Biosciences LLC
 Alpha Gene Inc.

 NONPROFIT
 ORGANIZATIONS

 CONTACT DR. SCHEELE

 

 


Founder
Chairman and Chief Scientific Officer, 11/93 - 2/98
President, and CEO, 11/93 - 6/97

In the early 1990s I retired from the academic world and entered the business world by founding AlphaGene, Inc., a genomics and proteomics company focused on the discovery of genes associated with disease states, particularly those in the brain including Alzheimer's disease, Parkinson's disease, temporal-lobe epilepsy, trauma and cancer. I served as Chairman, President and CEO of AlphaGene from 1993 through 1997.

Slide Presentation

•  Responsible for the strategic direction of the Company

•  Raised $10 million in four successful private placement financings

•  Prepared strategic business plans and marketing brochures.

•  Together, with Chief Financial Officer, prepared operating budgets, P&L statements, balance sheets, and financial projections.

•  Established initial operations in the Charlestown Navy Yard Biotech Park in 1994 (3,000 sq. ft.) and moved business to Woburn , MA to expand operations in 1996 (10,000 sq. ft. in 6/96; 15,000 sq. ft. in 9/97).

•  Supervised a recruitment program which increased the number of employees from three in 11/94 to 35, including eight Ph.D.s, in 6/97.

•  Responsible for presentations to investments bankers, the scientific community, and potential clients.

•  Supervised the establishment of five core technologies which enabled the first disease-based, full-length genomics platform, AlphaGenomicsT, for expressed human genes.

  • Molecular Biology - Synthesis of Full-Length, EXpressed gene (FLEX™) libraries. This patented technology provides the first technology platform capable of synthesizing cDNA libraries with high concentrations of full-length genes.
  • Gene Family Selection (FLEX-FamilySelect™) - Identifies new members of known gene families.
  • Gene Expression (FLEXpression™) - Uses high density microarray technology on biochips to identify disease-related genes according to their differential expression between normal and diseased tissues.
  • DNA sequencing (FLEX-AutoSeq™) - The first automated platform for rapidly obtaining high quality (6-10 fold coverage) DNA sequences in full-length cDNAs. Demonstrated throughput of 200 full-length genes per month.
  • Bioinformatics (FLEX-IS™) - Patent pending technology developed to automatically analyze the structural and functional features of full-length genes. The front end configured with an ease-of-use, point-and-click, drag-and-drop, icon-based query engine that substitutes for standard query language. Together, these two innovative features enable advanced data mining/discovery by individual scientists at platform-independent, point-of-research work stations.

•  Supervised the acquisition of scientific proof of principle for each of the core technologies.

•  Implemented successful commercialization of the Company's technology:

  • Genetics Institute contract signed in February, 1998.
  • NEN Life Sciences contract signed in August, 1998.